AMLX
Amylyx Pharmaceuticals, Inc.
A biopharmaceutical company that develops treatments for neurodegenerative diseases, founded in 2013 by two Brown University undergraduates, Joshua Cohen and Justin Klee. Their first drug, Relyvrio (sold as Albrioza in Canada), was approved in 2022 for ALS—the disease that gives the company its name, since "Amy" comes from "amyotrophic" and "lyx" nods to the breakdown of cells the drug targets. The company withdrew Relyvrio from the market in 2024 after a trial showed no clear benefit, though it kept the drug available free to patients already taking it.
CUSIP: 03237H101HealthcareUS1 holder
Total Value
$43.61M
Total Shares
2.96M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
